Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Aclarion, Inc. (ACON)
Company Research
Source: GlobeNewswire
BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise structure. The transaction materially strengthens Aclarion’s balance sheet, preserves capital structure integrity, and significantly extends the Company’s operating runway well past targeted near and medium-term catalysts while enhancing strategic flexibility as Nociscan continues to gain clinical and commercial traction. The Company believes its strengthened capital position fully supports continued execution across commercialization, evidence generation, and strategic partnerships in the lead up toward additional payor coverage. Financial Highli
Show less
Read more
Impact Snapshot
Event Time:
ACON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACON alerts
High impacting Aclarion, Inc. news events
Weekly update
A roundup of the hottest topics
ACON
News
- Aclarion Provides 2025 Update and 2026 Corporate Outlook [Yahoo! Finance]Yahoo! Finance
- Aclarion Provides 2025 Update and 2026 Corporate OutlookGlobeNewswire
- Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial DataGlobeNewswire
- Aclarion (NASDAQ:ACON) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACON&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> tMarketBeat
- Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)GlobeNewswire
ACON
Analyst Actions
- 11/20/25 - Ascendiant Capital
ACON
Sec Filings
- 1/13/26 - Form 8-K
- 1/9/26 - Form 8-K
- 1/9/26 - Form 424B5
- ACON's page on the SEC website